Biotech company Actigen has moved closer to clinical trials for rare disease treatment for Hunter syndrome, following a pre-Investigational New Drug (IND) meeting with the US Food and Drug Administration (FDA). The Cambridge-based biotech filed for a pre-IND advice meeting with the FDA to discuss the scientific, regulatory and safety issues related to developing […]
